跳至主要内容
临床试验/ACTRN12624000695505
ACTRN12624000695505尚未招募2 期

A prospective, open-label, single center, two arms study of amino acids infusion as renal protection during Lutetium-177 PSMA-I&T therapy: renal dosimetry assessment in patients with metastatic castrate-resistant prostate cancer.

Fiona Stanley Hospital0 个研究点目标入组 10 人开始时间: 2024年5月31日最近更新:

试验速览

阶段
2 期
状态
尚未招募
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Male

入选标准

  • 1.Male patients aged >18 yrs
  • 2.History of histologically confirmed prostate cancer
  • 3.Metastatic patients who are considered for ongoing treatment with 177Lu–PSMA-617
  • 4.Ability to understand and the willingness to sign a written informed consent

排除标准

  • 1.Life expectancy less than 6 months
  • 2.Unable to give informed consent
  • 3.Unable to comply with required scanning schedule.
  • 4.Other malignant tumors that are likely to express PSMA, such as salivary gland, renal or hepatocellular carcinoma

研究者

相似试验